The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

"Overall, the comprehensive meta-analysis highlights that SGLT2 inhibitors are effective across a wide range of kidney ...

Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

The SGLT2 inhibitors market is driven by the rising prevalence of diabetes and demand for effective antidiabetic therapies ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A new meta-analysis has shown that SGLT2 inhibitors do not lead to lower 28-day all-cause mortality ...